Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: Further test of the motivational salience hypothesis

Pharmacology Biochemistry and Behavior

Volumn 103, Issue 3, 2013, Pages 467-473

  Feng, Min ^a,b,c   Sui, Nan ^a   Li, Ming ^b  

^a INSTITUTE OF PSYCHOLOGY   (China)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Clozapine; Conditioned avoidance response; Motivational salience; Olanzapine; Within session decline

Indexed keywords

CLOZAPINE; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; MALE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; CLOZAPINE; CONDITIONING (PSYCHOLOGY); DRUG SYNERGISM; MALE; MOTIVATION; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 84868262733     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.09.013     Document Type: Article

References (45)

1. J.E. Barrett The emergence of behavioral pharmacology Mol Interv 2 2002 470 475
2. J.E. Barrett, J. Bergman, and B. Peter Dews and pharmacological studies on behavior J Pharmacol Exp Ther 326 2008 683 690
3. R.J. Beninger Dopamine and incentive learning: A framework for considering antipsychotic medication effects Neurotox Res 10 2006 199 209
4. R.J. Beninger, S.T. Mason, A.G. Phillips, and H.C. Fibiger The use of conditioned suppression to evaluate the nature of neuroleptic-induced avoidance deficits J Pharmacol Exp Ther 213 1980 623 627 (Pubitemid 10085171)
5. R.J. Beninger, S.T. Mason, A.G. Phillips, and H.C. Fibiger The use of extinction to investigate the nature of neuroleptic-induced avoidance deficits Psychopharmacology (Berl) 69 1980 11 18 (Pubitemid 10065165)
6. K.C. Berridge The debate over dopamine's role in reward: The case for incentive salience Psychopharmacology (Berl) 191 2007 391 431 (Pubitemid 46355895)
7. R.C. Bolles, and N.E. Grossen Function of the CS in shuttle-box avoidance learning by rats J Comp Physiol Psychol 70 1970 165 169
8. W.M. Davis, J. Capehart, and W.L. Llewellin Mediated acquisition of a fear-motivated response and inhibitory effects of chlorpromazine Psychopharmacologia 2 1961 268 276
9. P.B. Dews Interactions of behavioral effects of drugs Ann N Y Acad Sci 281 1976 50 63 (Pubitemid 8017611)
10. A. Dickinson, J. Smith, and J. Mirenowicz Dissociation of Pavlovian and instrumental incentive learning under dopamine antagonists Behav Neurosci 114 2000 468 483 (Pubitemid 30490894)
11. G. Fouriezos, P. Hansson, and R.A. Wise Neuroleptic-induced attenuation of brain stimulation reward in rats J Comp Physiol Psychol 92 1978 661 671 (Pubitemid 9000696)
12. J. Ichikawa, J. Dai, and H.Y. Meltzer DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release Brain Res 907 2001 151 155 (Pubitemid 32595524)
13. S. Kapur Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia Am J Psychiatry 160 2003 13 23 (Pubitemid 36042420)
14. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis Am J Psychiatry 158 2001 360 369 (Pubitemid 32205190)
15. S. Kapur, S.C. VanderSpek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy J Pharmacol Exp Ther 305 2003 625 631 (Pubitemid 36459179)
16. S. Kapur, R. Mizrahi, and M. Li From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis Schizophr Res 79 2005 59 68 (Pubitemid 41362593)
17. S. Kapur, O. Agid, R. Mizrahi, and M. Li How antipsychotics work-from receptors to reality NeuroRx 3 2006 10 21 (Pubitemid 43276632)
18. J.D. Leander Rate-dependent effects of drugs. II. Effects of some major tranquilizers on multiple fixed-ratio, fixed-interval schedule performance J Pharmacol Exp Ther 193 1975 689 700
19. J.D. Leander, and D.E. McMillan Rate-dependent effects of drugs. I. Comparisons of d-amphetamine, pentobarbital and chlorpromazine on multiple and mixed schedules J Pharmacol Exp Ther 188 1974 726 739
20. M. Li, J. Parkes, P.J. Fletcher, and S. Kapur Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases Pharmacol Biochem Behav 78 2004 811 819 (Pubitemid 39037744)
21. M. Li, P.J. Fletcher, and S. Kapur Time course of the antipsychotic effect and the underlying behavioral mechanisms Neuropsychopharmacology 32 2007 263 272 (Pubitemid 46106933)
22. M. Li, W. He, and R. Munro Amphetamine selectively enhances avoidance responding to a less salient stimulus in rats J Neural Transm 115 2008 773 776
23. M. Li, W. He, and A. Mead Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus Behav Pharmacol 20 2009 84 98
24. M. Li, T. Sun, C. Zhang, and G. Hu Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning Psychopharmacology (Berl) 212 2010 45 57
25. M. Li, T. Sun, and A. Mead Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT(2A/2C) receptors J Neural Transm 119 2012 497 505
26. D.E. McMillan, and J.L. Katz Continuing implications of the early evidence against the drive-reduction hypothesis of the behavioral effects of drugs Psychopharmacology (Berl) 163 2002 251 264
27. A. Mead, and M. Li Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: An interoceptive drug state mechanism J Psychopharmacol 24 2009 1045 1053
28. A. Mead, and M. Li Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: An interoceptive drug state mechanism J Psychopharmacol 24 2010 1045 1053
29. H.Y. Meltzer, S. Matsubara, and J.C. Lee The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs Psychopharmacol Bull 25 1989 390 392 (Pubitemid 20260244)
30. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: Their key role in drugs to treat schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 27 2003 1159 1172 (Pubitemid 37464960)
31. M.J. Millan, A. Dekeyne, and A. Gobert Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo Neuropharmacology 37 1998 953 955
32. R. Miller The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness Psychopharmacology (Berl) 92 1987 405 415 (Pubitemid 17105234)
33. R.E. Miller, J.V. Murphy, and A. Mirsky Persistent effect of chlorpromazine on extinction of an avoidance response AMA Arch Neurol Psychiatry 78 1957 526 530
34. S. Miyamoto, G.E. Duncan, C.E. Marx, and J.A. Lieberman Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol Psychiatry 10 2005 79 104 (Pubitemid 40139590)
35. R. Mizrahi, M. Kiang, D.C. Mamo, T. Arenovich, R.M. Bagby, and R.B. Zipursky The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders Schizophr Res 88 2006 111 118 (Pubitemid 44693243)
36. D.A. Overton Preclinical measurement of the amount of state-dependent learning produced by psychoactive drugs [proceedings] Psychopharmacol Bull 15 1979 51 52 (Pubitemid 9159199)
37. R.D. Porsolt, P.C. Moser, and V. Castagne Behavioral indices in antipsychotic drug discovery J Pharmacol Exp Ther 333 2010 632 638
38. G. Remington, and S. Kapur Antipsychotic dosing: how much but also how often? Schizophr Bull 36 2010 900 903
39. R.D. Spealman, R.T. Kelleher, S.R. Goldberg, J. DeWeese, and D.M. Goldberg Behavioral effects of clozapine: comparison with thioridazine, chlorpromazine, haloperidol and chlordiazepoxide in squirrel monkeys J Pharmacol Exp Ther 224 1983 127 134 (Pubitemid 13171040)
40. M.L. Wadenberg, A. Soliman, S.C. VanderSpek, and S. Kapur Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 2001 633 641 (Pubitemid 32995945)
41. G.R. Wenger Effects of clozapine, chlorpromazine and haloperidol on schedule-controlled behavior Pharmacol Biochem Behav 11 1979 661 667 (Pubitemid 10135921)
42. R.A. Wise Dopamine, learning and motivation Nat Rev Neurosci 5 2004 483 494 (Pubitemid 38715515)
43. R.A. Wise, J. Spindler, H. deWit, and G.J. Gerberg Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food Science 201 1978 262 264 (Pubitemid 8396751)
44. C. Zhang, and M. Li Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine Behav Pharmacol 23 2012 66 79
45. C. Zhang, Y. Fang, and M. Li Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence Pharmacol Biochem Behav 98 2011 155 160